Market Cap 1.99B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 3,257,586
Avg Vol 8,275,624
Day's Range N/A - N/A
Shares Out 305.38M
Stochastic %K 17%
Beta 1.14
Analysts Strong Sell
Price Target $10.50

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
Stocktradesmoon
Stocktradesmoon Jul. 15 at 7:01 PM
$ABCL AbCellera DEEP DIVE https://x.com/9_Invest_obey/status/2077295224049823754
0 · Reply
tradersunion353
tradersunion353 Jul. 15 at 5:39 PM
$ABCL Give me 13 dollars already Such a boring overhyped junk
1 · Reply
Samb2344
Samb2344 Jul. 15 at 4:46 PM
$ABCL cmon bro
0 · Reply
PamelaJorge270
PamelaJorge270 Jul. 15 at 3:32 PM
$ABCL has an interesting setup from a sentiment perspective. Not making a technical prediction, but the stock has repeatedly shown a pattern of sharp moves followed by pullbacks and rebounds. The bigger catalyst now is approaching: upcoming clinical readouts, potentially as early as the next earnings update. Technical patterns can be interesting, but for biotech names the real driver is always the data. If the readouts are positive, that will matter far more than any chart formation.
1 · Reply
Ckkung71
Ckkung71 Jul. 15 at 3:16 PM
$ABCL Everybody is excited of the results of phase 2 on 635. I asking you: Do you think they will wait fore the result or will they stay with 20-25% shorted stocks. If they do its must be a big institution No one else can do that. Or what?
1 · Reply
TradeIntelligence_
TradeIntelligence_ Jul. 15 at 1:32 PM
Top Multi-Year Growth Plays I’m Watching These are the companies with long-term potential in some of the biggest future markets: $QS -Next-generation battery technology with a focus on the future of energy storage. $SMR -Small modular nuclear reactor play targeting the growing demand for clean power. $JOBY -Electric aviation company aiming to transform urban transportation. $ABCL -AI-driven biotech platform combining advanced technology with drug discovery. $RXRX -AI-powered pharmaceutical company building the future of medicine. Long-term winners are often built before the market fully recognizes the opportunity.
1 · Reply
tradersunion353
tradersunion353 Jul. 15 at 1:10 PM
$ABCL over hyped underperforming pos how many years ceo and pumpers gonna do this drama “we dont care for share price we care science” hello clowns investors needs returns along with science
0 · Reply
Ckkung71
Ckkung71 Jul. 15 at 6:30 AM
$ABCL Higher then ever..
1 · Reply
snowPOW
snowPOW Jul. 15 at 4:58 AM
$ABCL I don't even feel bad averaging up. I plan to make a buy, relatively soon. Big for me, probably insignificant to a chart. This has been cheap for so long, I should've bought before. To 20B, the launch pad to multiples. Undervalued. Hasn't even been set up for lift off
3 · Reply
Samb2344
Samb2344 Jul. 15 at 2:26 AM
$ABCL higher
0 · Reply
Latest News on ABCL
AbCellera upgraded to Buy from Hold at Benchmark

2026-07-07T10:35:14.000Z - 8 days ago

AbCellera upgraded to Buy from Hold at Benchmark

JAZZ


AbCellera apponts Lynn Seely to board of directors

2026-07-06T13:15:29.000Z - 9 days ago

AbCellera apponts Lynn Seely to board of directors

LYEL


AbCellera Appoints Dr. Lynn Seely to its Board of Directors

Jul 6, 2026, 9:00 AM EDT - 9 days ago

AbCellera Appoints Dr. Lynn Seely to its Board of Directors


AbCellera appoints Victor Sandor to board of directors

2026-06-05T13:05:56.000Z - 5 weeks ago

AbCellera appoints Victor Sandor to board of directors


AbCellera price target raised to $8 from $7 at Stifel

2026-05-12T10:58:11.000Z - 2 months ago

AbCellera price target raised to $8 from $7 at Stifel


AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Earnings Call Transcript: Q1 2026


AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Earnings release: Q1 2026


AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Quarterly report: Q1 2026


AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 2 months ago

AbCellera Biologics Slides: Q1 2026


AbCellera initiated with an Overweight at Cantor Fitzgerald

2026-05-05T10:36:31.000Z - 2 months ago

AbCellera initiated with an Overweight at Cantor Fitzgerald


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 2 months ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera initiated with a Buy at JonesResearch

2026-04-09T20:10:26.000Z - 3 months ago

AbCellera initiated with a Buy at JonesResearch


AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025


AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Annual report: Q4 2025


AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Earnings release: Q4 2025


AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 5 months ago

AbCellera Biologics Slides: Q4 2025


AbCellera reports FY25 EPS (49c) vs. (55c) last year

2026-02-24T21:15:21.000Z - 5 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year


AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 5 months ago

AbCellera Reports Full Year 2025 Business Results


AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 6 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 8 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors


AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025


AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Quarterly report: Q3 2025


AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Earnings release: Q3 2025


AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 8 months ago

AbCellera Biologics Slides: Q3 2025


AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 8 months ago

AbCellera Reports Q3 2025 Business Results


AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 11 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer


AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q2 2025


AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q2 2025


AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q2 2025


AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q2 2025


AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 1 year ago

AbCellera Biologics Slides: Corporate Presentation


AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025


AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025


AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025


AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025


AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024


AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024


AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024


AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024


AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results


AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025


AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024


AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024


AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024


AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024


AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q2 2024


AbCellera Biologics Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q2 2024


AbCellera Biologics Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q2 2024


AbCellera Biologics Slides: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q2 2024


AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q2 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024


AbCellera Biologics Quarterly report: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q1 2024


AbCellera Biologics Earnings release: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q1 2024


AbCellera Biologics Slides: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q1 2024


AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results


Stocktradesmoon
Stocktradesmoon Jul. 15 at 7:01 PM
$ABCL AbCellera DEEP DIVE https://x.com/9_Invest_obey/status/2077295224049823754
0 · Reply
tradersunion353
tradersunion353 Jul. 15 at 5:39 PM
$ABCL Give me 13 dollars already Such a boring overhyped junk
1 · Reply
Samb2344
Samb2344 Jul. 15 at 4:46 PM
$ABCL cmon bro
0 · Reply
PamelaJorge270
PamelaJorge270 Jul. 15 at 3:32 PM
$ABCL has an interesting setup from a sentiment perspective. Not making a technical prediction, but the stock has repeatedly shown a pattern of sharp moves followed by pullbacks and rebounds. The bigger catalyst now is approaching: upcoming clinical readouts, potentially as early as the next earnings update. Technical patterns can be interesting, but for biotech names the real driver is always the data. If the readouts are positive, that will matter far more than any chart formation.
1 · Reply
Ckkung71
Ckkung71 Jul. 15 at 3:16 PM
$ABCL Everybody is excited of the results of phase 2 on 635. I asking you: Do you think they will wait fore the result or will they stay with 20-25% shorted stocks. If they do its must be a big institution No one else can do that. Or what?
1 · Reply
TradeIntelligence_
TradeIntelligence_ Jul. 15 at 1:32 PM
Top Multi-Year Growth Plays I’m Watching These are the companies with long-term potential in some of the biggest future markets: $QS -Next-generation battery technology with a focus on the future of energy storage. $SMR -Small modular nuclear reactor play targeting the growing demand for clean power. $JOBY -Electric aviation company aiming to transform urban transportation. $ABCL -AI-driven biotech platform combining advanced technology with drug discovery. $RXRX -AI-powered pharmaceutical company building the future of medicine. Long-term winners are often built before the market fully recognizes the opportunity.
1 · Reply
tradersunion353
tradersunion353 Jul. 15 at 1:10 PM
$ABCL over hyped underperforming pos how many years ceo and pumpers gonna do this drama “we dont care for share price we care science” hello clowns investors needs returns along with science
0 · Reply
Ckkung71
Ckkung71 Jul. 15 at 6:30 AM
$ABCL Higher then ever..
1 · Reply
snowPOW
snowPOW Jul. 15 at 4:58 AM
$ABCL I don't even feel bad averaging up. I plan to make a buy, relatively soon. Big for me, probably insignificant to a chart. This has been cheap for so long, I should've bought before. To 20B, the launch pad to multiples. Undervalued. Hasn't even been set up for lift off
3 · Reply
Samb2344
Samb2344 Jul. 15 at 2:26 AM
$ABCL higher
0 · Reply
DeMampCamp
DeMampCamp Jul. 14 at 11:53 PM
$ABCL If there’s one piece of advice I have for management as far as ABCL635 is don’t publicly announce when the results are out, that keeps the short term flippers and shorts on their toes! Just release the PR and discuss the results following said release. Now what they said, I don’t know all of the SEC rules, so I may be missing something! Nice to finally see some green today!
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 14 at 10:47 PM
$ABCL $ABCL One leadership trait I appreciate is vision, and Carl Hansen has it. Everyone's talking about antibody discovery now, but AbCellera decided to go all-in on this tech over a decade ago. How did he know back then that therapeutic antibodies were the future? What did he see? When Hansen founded AbCellera in 2012 out of his academic lab at the University of British Columbia, his foresight specifically zeroed in on antibodies as the ultimate therapeutic modality. He explained the foundational thesis of the company by stating: "the core idea was that we were going to use microfluidics to be able to enable very rapid scalable analysis of the properties of individual cells and that the cells we're going to look at were the immune cells... because those cells... make different molecules called antibodies and it turns out people actually care about antibodies because they are the largest and still, in an absolute terms, the fastest growing class of therapeutics that exist".
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 14 at 10:46 PM
$ABCL His foresight was fundamentally rooted in identifying a massive technological shift and recognizing that the biotechnology industry lacked the necessary tools to efficiently harness it. Hansen's initial intuition about the future of medicine actually prompted him to abandon a promising career path in physics. After completing his undergraduate training, he realized that the field had largely moved past its golden age of fundamental discovery. Recognizing the inflection point occurring in the life sciences around 2001, particularly with the sequencing of the human genome, he noted, "I had some intuition that biology was really taking off so I moved from my physics training and I tried to get into biology". He observed that the cost and speed of reading DNA was advancing at a rate that "outpaces Moore's law by orders of magnitude," leading him to conclude that biotechnology would become the most important sector for scientific discovery in the coming decades.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 14 at 10:45 PM
$ABCL Instead of taking the traditional, highly risky route of trying to develop a single drug from scratch, Hansen’s early vision was to solve the industry's bottleneck in drug creation AbCellera believes there has been chronic underinvestment in developing drug-creation capabilities for antibody medicines. Hansen recognized that the process of discovering drugs was simply too slow and prone to failure, so he positioned AbCellera as a technology provider. This early vision of acting as an advanced technological engine for the industry ultimately allowed AbCellera to build a massive portfolio of downstream economic stakes in partnered programs without bearing the traditional costs and risks of clinical trials. It now also serves as the foundation for their internal antibody pipeline.
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 14 at 10:45 PM
$ABCL Looking forward, Hansen's foresight continues to anticipate the evolution of antibody therapies. He notes that while the initial multi-billion-dollar market explosion was driven by simple, standard monoclonal antibodies, the future lies in highly engineered formats. He's stated that "what you're seeing now that's the next wave is bispecific antibodies antibody drug conjugates multispecific antibodies radioisotope antibodies there's a Cambrian explosion of modalities that use the advantages of antibodies in unique ways," predicting that this will be the next massive wave of innovation in therapeutic medicines. According to management, global therapeutic antibody sales amounted to about $300 billion in 2025 and the market is expected to grow to over $500 billion by 2030.
0 · Reply
OctahedronOmega
OctahedronOmega Jul. 14 at 9:48 PM
$ABCL More of a broader FDA signal than a direct near-term catalyst for one biotech. FDA is still refining how it handles AI-driven medical software and digital health. The key watchpoint: it’s collecting input through Aug 13, 2026 on some software functions that fall outside medical device classification and on patient safety.
0 · Reply
TradeX_
TradeX_ Jul. 14 at 8:00 PM
Looks like BMGL might be the next 800% runner. Crazy market! Every micro float ticker has been going parabolic this month. Would not be surprised if they send BMGL up now. BMGL starting to make its move now! Only 750k shares outstanding! 💎 $ABCL $FBIO $TGTX 0s
3 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 14 at 7:10 PM
$ABCL $ABCL bulls holding strong at the $6.52 support 💪 That’s the top of wave 1. Wave 4 usually doesn’t break below it in Elliott Wave. Clean setup for a bounce into wave 5 🚀 Who else seeing this? 👀
0 · Reply
Stocktradesmoon
Stocktradesmoon Jul. 14 at 7:04 PM
$ABCL There is possibility ABCL635 phase 2 Topline data will be on 2nd Quarter call for $ABCL Blinded Ph2 is 1 dose +12 weeks of data collection. First ladies dosed in JAN 26. Could be finished if they had all dosed in FEB/MAR 26 and Carl mentioned high interest.
1 · Reply
Doozio
Doozio Jul. 14 at 5:13 PM
MNDY 🐑 $$$ patterns retests ONTO turnaround Tuesday’s are as easy as $ABCL n XYZ ENTA 🐒🍌🧠⏰♾️
0 · Reply
GoldenGateGamma
GoldenGateGamma Jul. 14 at 5:06 PM
Epictetus said, “No great thing is created suddenly.” That’s how I view $ABCL. The hardest part of owning a long-term idea is watching the stock do nothing while the market runs higher. Every pullback tests your conviction, but real reratings rarely happen from one headline or one green candle. They happen when a company keeps executing until the market is forced to recognize the progress. The patience part is usually where the edge is built.
0 · Reply
tradersunion353
tradersunion353 Jul. 14 at 3:16 PM
$ABCL hey paper traders who get psyched up every time this POS drops how is your adding and loading paper trading working??? DEMMP clown is that you who is creating multiple accounts to pump thjis POS
2 · Reply